BioSpace News Archive

A considerable rise in the cases of upper respiratory tract infections due to factors like dense pollution levels and frequent climate changes may bring good growth opportunities for the upper respiratory tract infection treatment market during the forecast period of 2019-2029.

Various studies conducted recently contend that rehabilitation treatments and therapeutic devices offered at home settings are equally effective as compared to hospitals for a number of surgeries.

Mogrify Ltd, a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board.

Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m. ET to Discuss Commercialization Progress.

NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its proposed IND and Phase I/II study for its lead candidate, CBX-12 (alphalex™-exatecan). Cybrexa plans to submit the IND application for CBX

Nasus Pharma announced data from a preclinical collaboration with the University of Virginia School of Medicine that demonstrated TaffiX®, the Company’s innovative nasal powder inhaler that effectively blocks viruses from reaching nasal mucosa, was able to block more than 99% of SARS-CoV-2 viruses.

Regeneron Pharmaceuticals, Inc. announced that, as part of Operation Warp Speed, the BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have awarded Regeneron a $450 million contract to manufacture and supply REGN-COV2.

Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China

Strongbridge Biopharma plc, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, announced that at the request of the Board of Directors, John H. Johnson has agreed to become the chief executive officer of Strongbridge.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that dosing o